title: Functional and phenotypic changes in monocytes from patients with tuberculosis are reversed with treatment.
abstract: Alterations of monocyte/macrophages have been reported in patients with tuberculosis (TB), but their significance is poorly understood. Blood mononuclear cells from patients with different clinical forms of TB, at various times of anti-TB treatment, and healthy tuberculin positive individuals, were double-stained for CD14 plus CD206, TLR-2, IFN-gammaR1, CD40, HLA-DR, CD36 and CD163, and analyzed by flow cytometry. Monocytes were infected with Mycobacterium tuberculosis H37Rv and 24h later the phenotype, induction of necrosis and apoptosis and production of tumor necrosis factor TNFalpha, interleukin (IL)-10 and IL-12p40 were determined. TB patients presented higher percentage of CD14+ cells but lower percentage of CD14+DR+ and CD14+CD36+ cells. Expression of CD14, HLA-DR and CD36 was decreased in TB patients. Normal percentages and expression were restored during anti-TB treatment. Monocytes from TB patients underwent necrosis and apoptosis after M. tuberculosis infection, whereas monocytes from healthy controls exhibited only apoptosis. Anti-TB treatment reverted necrosis. There were no differences between the various clinical forms of TB. In vitro M. tuberculosis infection decreased expression of the membrane molecules studied. HLA-DR and CD36 inhibition correlated with induction of apoptosis. Restoration of monocyte alterations during anti-TB treatment suggests that such alterations may be caused by the high M. tuberculosis load present during active disease.
authors.affiliation: Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Sede de Investigación Universitaria, Universidad de Antioquia, Cra 53 No. 61-30, Lab. 410, Medellín, Colombia.
authors.forename: María D
authors.initials: MD
authors.lastname: Sánchez
authors.forename: Yoenis
authors.initials: Y
authors.lastname: García
authors.forename: Carlos
authors.initials: C
authors.lastname: Montes
authors.forename: Sara C
authors.initials: SC
authors.lastname: París
authors.forename: Mauricio
authors.initials: M
authors.lastname: Rojas
authors.forename: Luis F
authors.initials: LF
authors.lastname: Barrera
authors.forename: Mauricio A
authors.initials: MA
authors.lastname: Arias
authors.forename: Luis F
authors.initials: LF
authors.lastname: García
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D018955:CD36 Antigens / Q000096:biosynthesis / Q000276:immunology; D005260:Female; D006684:HLA-DR Antigens / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology* / Q000382:microbiology; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D010641:Phenotype; D014376:Tuberculosis / Q000097:blood / Q000276:immunology* / Q000382:microbiology / Q000628:therapy*
chemical_list: D000995:Antitubercular Agents; D018955:CD36 Antigens; D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors